Chances, risks and limitations of neoadjuvant therapy in surgical oncology

by Lordick Florian, Gockel Ines
Published 2016-09-01

A phase II study for metabolic <it>in vivo </it>response monitoring with sequential ¹⁸FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastat...

by Berger Anne, von Gall Carl, Abel Ulrich, Delorme Stefan, Kloor Matthias, Ose Jennifer, Weber Tim, Stange Annika, Haag Georg, Haberkorn Uwe, Lordick Florian, Jäger Dirk
Published 2012-03-01

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-...

by Weichert Wilko, Lordick Florian, Haberkorn Uwe, Weitz Jürgen, Haag Georg M, Stange Annika, von Gall Carl, Lorenzen Sylvie, Abel Ulrich, Debus Jürgen, Jäger Dirk, Münter Marc W
Published 2011-06-01

Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a...

by Rahbari Nuh N, Lordick Florian, Fink Christine, Bork Ulrich, Stange Annika, Jäger Dirk, Luntz Steffen P, Englert Stefan, Rossion Inga, Koch Moritz, Büchler Markus W, Kieser Meinhard, Weitz Jürgen
Published 2012-04-01

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of...

by Luber Birgit, Deplazes Joëlle, Keller Gisela, Walch Axel, Rauser Sandra, Eichmann Martin, Langer Rupert, Höfler Heinz, Hegewisch-Becker Susanna, Folprecht Gunnar, Wöll Ewald, Decker Thomas, Endlicher Esther, Lorenzen Sylvie, Fend Falko, Peschel Christian, Lordick Florian
Published 2011-12-01